Fleet Bioprocessing will be attending MEDICA 2026 in Düsseldorf, exploring point-of-care diagnostics, biomarkers, emerging technologies and developments relevant to immunoassays, lateral flow and bioconjugation.
Quality control in immunoassay development ensures reliable diagnostic results through calibration standards, internal controls, validation studies, and robust assay monitoring.